{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:28:13Z","timestamp":1782905293447,"version":"3.54.5"},"reference-count":56,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2024,5,3]]},"DOI":"10.1080\/14712598.2024.2354371","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:51:55Z","timestamp":1715320315000},"page":"389-397","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0255-3138","authenticated-orcid":false,"given":"Jaromir","family":"Tomasik","sequence":"first","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Bilicki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz W\u0142adys\u0142aw","family":"Basak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26301"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02176-0"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01739-2"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018295"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.09.008"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169219"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.043"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_5_12_1","unstructured":"Higgins JT Chandler J Cumpston M et al. Cochrane Handbook for systematic reviews of interventions version 6.4. Cochrane; 2023 [cited 2023 Aug]. Available from: www.training.cochrane.org\/handbook"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_3_5_14_1","unstructured":"Team RC. R: a language and environment for statistical computing. Vienna aust(RI)a: R Foundation for Statistical Computing; 2023 Available from: <https:\/\/www.R-project.org\/>"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03"},{"key":"e_1_3_5_17_1","unstructured":"Viechtbauer W. Comparing estimates of Independent meta-analyses or subgroups 2023. [citedDec 2023 19] Available from: http:\/\/www.metafor-project.org\/doku.php\/tips:comp_two_independent_estimates#separate_meta-analyses"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009432"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-6367(23)00071-4"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146236"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138538"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S312904"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002292"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(20)30873-9"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136659"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009260"},{"key":"e_1_3_5_27_1","first-page":"S31","article-title":"Subcutaneous epcoritamab in relapsed or refractory large B-Cell lymphoma: pivotal results from the phase 2 EPCORE NHL-1 trial","volume":"97","author":"Catherine T","year":"2022","unstructured":"Catherine T, Tycel P, Herve G, et al. Subcutaneous epcoritamab in relapsed or refractory large B-Cell lymphoma: pivotal results from the phase 2 EPCORE NHL-1 trial. Am J Hematol. 2022;97:S31\u2013S2.","journal-title":"Am J Hematol"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016945"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01325-3"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19057"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.87_2879"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000851240.74602.7c"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-144350"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102516"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123742"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7569"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18383"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008240"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000847588.33528.e3"},{"key":"e_1_3_5_40_1","first-page":"603","article-title":"Lenalidomide-rituximab in high risk relapsed\/refractory diffuse large b cell lymphoma: a single institution experience","volume":"4","author":"Conde-Royo D","year":"2020","unstructured":"Conde-Royo D, Juarez-Salcedo LM, Shah BD, et al. Lenalidomide-rituximab in high risk relapsed\/refractory diffuse large b cell lymphoma: a single institution experience. Hemasphere. 2020;4:603.","journal-title":"Hemasphere"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148751"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006245"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136279"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.737645"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006801"},{"key":"e_1_3_5_46_1","first-page":"280","article-title":"POLA-BR after CAR-T cell therapy failure in R\/R diffuse large B-CELL lymphoma","volume":"56","author":"Smykova O","year":"2021","unstructured":"Smykova O, Markelrov V, Lepik K, et al. POLA-BR after CAR-T cell therapy failure in R\/R diffuse large B-CELL lymphoma. Bone Marrow Transplant. 2021;56:280\u2013281.","journal-title":"Bone Marrow Transplant"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.86_2880"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135835"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.07.438"},{"issue":"2","key":"e_1_3_5_50_1","first-page":"153","article-title":"Management of single site localized early relapse after CART cell therapy in DLBCL: a single center experience","volume":"107","author":"Bramanti S","year":"2021","unstructured":"Bramanti S, Mannina D, Navarria P, et al. Management of single site localized early relapse after CART cell therapy in DLBCL: a single center experience. Tumori. 2021;107(2 SUPPL):153.","journal-title":"Tumori"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2021.09.001"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012634"},{"key":"e_1_3_5_53_1","first-page":"231","article-title":"Nivolumab as salvage therapy in patients who failed to achieve complete remission after anti-CD19 CAR T-cell therapy for DLBCL","volume":"55","author":"Gazeau N","year":"2020","unstructured":"Gazeau N, Beauvais D, Manier S, et al. Nivolumab as salvage therapy in patients who failed to achieve complete remission after anti-CD19 CAR T-cell therapy for DLBCL. Bone Marrow Transplant. 2020;55:231\u2013232.","journal-title":"Bone Marrow Transplant"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i19.6555"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010016"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70375-4"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.771"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010930"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2024.2354371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:45:24Z","timestamp":1727225124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2354371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,3]]}},"alternative-id":["10.1080\/14712598.2024.2354371"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2024.2354371","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}